Physician profile
Javier Carrillo
NPI 1427417468
$3,276.04
in general payments reported to CMS, 2019-2025
27 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.72 · 2023: $959 · 2024: $1,092 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,059.11 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $512.93 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $314.21 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.67 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.08 | 2024-2025 | Xifaxan |
| Esperion Therapeutics, INC. | $104.72 | 2023-2025 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $102.96 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Corcept Therapeutics | $100.79 | 2024 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $100.05 | 2023-2025 | |
| Pfizer INC. | $98.68 | 2023-2025 | |
| Atland Pharmaceuticals, LLC | $81.61 | 2024 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Lundbeck LLC | $71.70 | 2024 | Rexulti |
| Vanda Pharmaceuticals INC. | $71.01 | 2023-2024 | Fanapt, Hetlioz |
| Shield Therapeutics INC | $60.16 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $56.15 | 2025 | Capvaxive, Gardasil 9 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $49.36 | 2025 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $30.61 | 2023 | Gemtesa |
| Ani Pharmaceuticals, INC. | $25.82 | 2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $25.02 | 2024 | Freestyle Libre 3 |
| Abbvie INC. | $23.57 | 2023 | |
| Janssen Biotech, INC. | $21.42 | 2023 | |
| Inspire Medical Systems, INC. | $20.68 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $16.38 | 2024 | Arexvy, Shingrix |
| Idorsia Pharmaceuticals US INC | $15.95 | 2023 | Quviviq |
| Dexcom, INC. | $14.99 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $14.88 | 2024 | |
| Biogen, INC. | $13.53 | 2023 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Carrillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.